FDA Grants Orphan Drug Designation to BDC-1001 in Gastric Cancers
The FDA has given an orphan drug designation to BDC-1001 for the treatment of patients with gastric cancers, including gastroesophageal junction cancer.
Source: onclive.com
Stay updated with breaking news from Dc 1001 . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has given an orphan drug designation to BDC-1001 for the treatment of patients with gastric cancers, including gastroesophageal junction cancer.